Most Read Articles
Pearl Toh, 15 hours ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 2 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Intestinal ultrasound useful for evaluating disease, therapeutic response in UC

09 Feb 2020

Intestinal ultrasound is useful in monitoring disease course and evaluating short-term treatment response in patients with ulcerative colitis (UC) and may serve as a viable point-of-care tool in general practice, according to data from the TRUST&UC* study.

TRUST&UC enrolled 253 consecutive patients with a diagnosis of a proctosigmoiditis, left-sided colitis or pancolitis currently in clinical relapse (defined as Short Clinical Colitis Activity Index [SCCAI] ≥5).

A total of 224 patients (88.5 percent) had an increased bowel wall thickness (BWT) in the descending or sigmoid colon at baseline, as assessed using duplex/Colour Doppler ultrasonography. Of these, half had a left-sided colitis while the other half had a pancolitis.

The number of patients with an increased BWT in the sigmoid or descending colon decreased significantly within the first 2 weeks of the study, from 89.3 percent to 38.6 percent and from 83.0 percent to 42.9 percent (p-both<0.001), respectively. This remained low at weeks 6 and 12 (sigmoid colon: 35.4 percent and 32.0 percent; descending colon: 43.4 percent and 37.6 percent; p<0.001).

BWT normalization and clinical response following 12 weeks of treatment were strongly correlated, such that 90.5 percent of patients with normalized BWT had symptomatic response (p<0.001).

The present data provide evidence that monitoring BWT alone has the potential to predict the therapeutic response, which should be verified in future studies, according to researchers.

*The study TRansabdominal Ultrasonography of the bowel in Subjects with IBD To monitor disease activity with UC

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 15 hours ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 2 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.